Ajinomoto Bio-Pharma Services is taking full control of an API manufacturing facility in India as the CDMO continues to bulk up in a market that favors companies that can do it all.
Ajinomoto Bio-Pharma today announced it is buying the 50% share of the joint venture still owned by Indian partner Granules OmniChem (GOC). The JV was first established in 2011 and operates a plant in Visakhapatnam that manufactures small-molecule intermediates and active pharmaceutical ingredients (APIs). Terms of the deal were not disclosed.
“GOC has been a well-run producer of high-quality API since its formation, which was designed, constructed and is managed based on our Belgian sites’ GMP operating standards and quality systems,” Ajinomoto Bio-Pharma CEO David Enloe said in a statement.
This move follows several others as the company expands and consolidates its operations. In 2018, then Ajinomoto Althea and U.S.-based OmniChem combined their large- and small-molecule operations. Ajinomoto Bio-Pharma Services, which is a wholly owned subsidiary of Tokyo-based Ajinomoto, earlier this year folded GeneDesign into its operations.
The CDMO in 2016 acquired the Japanese CDMO that produces nucleic acid drugs but kept it as a separate company. The operation has a 2,000-square-meter facility in Osaka that manufactures oligonucleotide APIs and does custom synthesis.
The moves by the company mirror some of the steps taken by other CDMOs to expand operations in a variety of areas. Somerset, New Jersey-based Catalent, for one, this year laid out $1.2 billion for Paragon Bioservices to bust into the gene therapy realm. It then followed that up with a $40 million investment at its manufacturing facility in Winchester, Kentucky, to boost its formulation and controlled-release tablet and capsule manufacturing.
By Eric Palmer
Source: Fierce Pharma
Coeliac disease causes long-term damage to patients’ small intestine and puts them at risk of other medical conditions. Treatment options are urgently needed. Allie Nawrat explores the promise of larazotide, the drug in development currently leading the pack.
Bone Therapeutics has announced positive 24-month follow-up results from its phase IIa study of Allob, its allogeneic cell therapy, in patients undergoing lumbar spinal fusion procedures.
Belgian pharma company UCB has agreed to acquire a new campus to further support its operations in the UK.